Brickell Biotech Profit Margin

The latest profit margin for BBI is -643.48% as of June 2022. That compares with -9449.55% in the prior-year period — up 93.2% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Brickell Biotech's historical trend and sector peers before judging valuation or financial health.

Over the past year, BBI's profit margin moved from -9449.55% to -643.48% — a 93.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Brickell Biotech's valuation or profitability profile.

Against Healthcare companies, BBI currently prints -643.48% for profit margin, while the sector average sits near 13.89%. That is roughly 4732.7% below the sector mean. Large gaps often invite a closer look at Brickell Biotech's growth, margins, and balance sheet.

Profit Margin shows how effectively Brickell Biotech converts resources into returns. At -643.48%, BBI may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -9449.55% in the prior-year period — up 93.2% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting BBI's profit margin (-643.48%), review year-over-year change from -9449.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.